FLT3 and acute myeloid leukemia: Whilst AR is commonly used in line with international guidance in FLT3 mutation reporting, the benefits of reporting mutational burden in NPM1mut cases has yet to be fully demonstrated and is currently debated, with some research indicating that an increased mutational burden in NPM1mut AML leads to a significant reduction in overall and event free survival [89].